Cosentyx intravenous — Cigna

Initial criteria

• Patient is age ≥ 2 years
• The medication is prescribed by or in consultation with a rheumatologist or a dermatologist

Reauthorization criteria

• Patient has been established on Cosentyx subcutaneous or intravenous for at least 6 months
• Patient meets at least ONE of the following: when assessed by at least one objective measure, patient experienced a beneficial clinical response from baseline OR compared with baseline, patient experienced an improvement in at least one symptom such as less joint pain, morning stiffness, or fatigue; improved function or activities of daily living; decreased soft tissue swelling in joints or tendon sheaths

Approval duration

initial 6 months, renewal 1 year